Interpace Pharma Solutions recognizes the significant need for improved assay technology to evaluate target gene expression in tissues, particularly for preclinical studies. Unfortunately, most in situ RNA detection techniques lack the robustness and sensitivity to reliably detect expression of many target genes in a variety of species and tissue types.
RNAscope® in situ hybridization (ISH) is an Interpace Pharma Solutions offering that can visualize, localize, and quantify gene expression within a single assay, to help advance RNA biomarker analysis for gene and cell-based therapies.
“RNAscope is an excellent addition to our extensive immuno-oncology assay portfolio and helps to unlock the full potential of RNA biomarkers.
RNAscope technology can predict target organ toxicity in preclinical models, confirm correct target site and on-target activity, and allow the ability to rapidly screen target nominees—across virtually any gene, species, tissue, and laboratory workflow.”Learn More About RNAscope Technology
Widely used immunohistochemistry (IHC) techniques rely on the availability of antibodies which can be expensive and time-consuming to develop. In some cases, it may not be feasible to develop reliable antibodies.
Techniques including microarrays and PCR provide useful molecular profiles, but clinically relevant cell and tissue context information is often lost along with the spatial variation of gene expression patterns.
RNAscope is a novel RNA ISH technology with a unique probe design strategy that allows simultaneous signal amplification and background suppression to achieve single-molecule visualization while preserving tissue morphology. The technology enables RNA target expression analysis within intact cells and tissues with high sensitivity and specificity.
Based on a proprietary double Z probe design, RNAscope ISH enables the detection of almost any RNA biomarker with single-molecule sensitivity and high specificity in tissues. It provides a universal solution to characterize tissue distribution of drug targets and biomarkers in a highly specific, sensitive manner.
Hybridization requires Double Z binding – providing simultaneous signal amplification and background noise control
The RNAscope approach to ISH allows multiplex detection for up to four target genes and up to 12 RNA targets per slide when using the HiPlex workflow.
The ability to analyze gene expression in situ, compounded with the high sensitivity and specificity, make RNAscope a preferred platform for translating RNA biomarkers into clinical use.
The unique “double Z” probes simultaneously provide signal amplification and background noise control, resulting in high sensitivity and specificity. Single-molecule visualization of the assay yields quantitative RNA and cell-specific expression within intact tissue architecture.
RNAscope ISH can streamline immune checkpoint target identification; visualize in vivo delivery of CAR-T therapeutic products; and differentiate therapeutic gene sequence from endogenous transcripts selection, even when there is no known or validated antibody. RNAscope unlocks the full potential of RNA biomarkers and is an excellent addition to Interpace’s extensive immuno-oncology assay portfolio.
RNAscope technology can help predict target organ toxicity in preclinical models, confirm correct target sites and on-target activity, and allows the ability to rapidly screen target nominees.
At Interpace Pharma Solutions, we use RNAscope to support our clients with:
RNAscope is a tool for biomarker and companion diagnostic identification. By detecting biomarker targets in situ, our clients can combine molecular information with histopathology for easier disease classification.
Streamline target identification and selection
EXAMPLE USE: Region of interest (ROI) selection in spatial profiling
Visualize in vivo delivery of therapeutic gene expression and vector sequences (viral or non-viral) to identify:
EXAMPLE USE: Confirm trafficking of CAR-T therapy to correct target site and on-target activity
Overcome the limitations of IHC
EXAMPLE USE: Application when antibodies are unavailable, or antibody performance is not idealTalk With Us About Your RNAscope Use Case and Learn How We Can Help!
Unlock the full potential of RNA biomarkers. RNAscope® ISH Provides High Sensitivity and Specificity
Quantitative RNA Expression
RNAscope provides the benefits of in situ analysis for RNA biomarkers and can enable rapid development of RNA ISH-based molecular diagnostic assays.
Biomarkers based on DNA, RNA, and proteins are used for cancer diagnosis, prognosis, and therapy guidance, boosting the emergence of personalized medicine. RNA biomarkers or gene expression signatures have emerged as a major class of cancer biomarkers, thanks to widespread use of genome-wide gene expression profiling technologies.
Existing RNA extraction processes destroy the tissue context of gene expression measurements, making it impossible to map the observed signals to individual cells. Single-molecule visualization in individual cells is achieved through RNAscope’s novel probe design strategy and a hybridization-based signal amplification.
Catalog and Made-to-Order Probes
Interpace Pharma Solutions provides access to a library of double "Z" oligo probes designed to hybridize to your specific RNA target of interest. We have availability of over 13,000 RNA targets in over 140 species including human, mouse, rat, dog, cow, zebrafish, rabbit, pig, chicken, monkeys and over 100 viruses.
Our experts will work with you to design in situ hybridization RNA probes for virtually ANY gene in ANY genome for visualization in ANY tissue or Cell
RNAscope ISH is one of the SpatialPlex™ services provided by Interpace Pharma Solutions
SpatialPlex services can: